Solid-state stability studies of crystal form of tebipenem
The aim of this study was to determine the kinetic and thermodynamic parameters of tebipenem degradation in the solid state. The process was analyzed based on the results obtained by a high performance liquid chromatography (HPLC) method using ultraviolet diode-array detector (DAD)/electrospray ionization tandem mass spectrometry (Q-TOF-MS/MS), Fourier transform infrared spectroscopy (FT-IR) and Raman spectroscopic (RS) studies. In dry air, the degradation of tebipenem was a first-order reaction depending on the substrate concentration while at an increased relative air humidity tebipenem was degraded according to the kinetic model of autocatalysis. The thermodynamic parameters: energy of activation (Ea), enthalpy (ΔH(≠a)) and entropy (ΔS(≠a)) of tebipenem degradation were calculated. Following a spectroscopic analysis of degraded samples of tebipenem, a cleavage of the β-lactam bond was proposed as the main degradation pathway, next confirmation using HPLC-Q-TOF-MS/MS method.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Drug development and industrial pharmacy - 42(2016), 2 vom: 22., Seite 238-44 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Talaczyńska, Alicja [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 11.10.2016 Date Revised 30.12.2016 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3109/03639045.2015.1044902 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM249659514 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM249659514 | ||
| 003 | DE-627 | ||
| 005 | 20231224154050.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3109/03639045.2015.1044902 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0832.xml |
| 035 | |a (DE-627)NLM249659514 | ||
| 035 | |a (NLM)26043654 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Talaczyńska, Alicja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Solid-state stability studies of crystal form of tebipenem |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.10.2016 | ||
| 500 | |a Date Revised 30.12.2016 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The aim of this study was to determine the kinetic and thermodynamic parameters of tebipenem degradation in the solid state. The process was analyzed based on the results obtained by a high performance liquid chromatography (HPLC) method using ultraviolet diode-array detector (DAD)/electrospray ionization tandem mass spectrometry (Q-TOF-MS/MS), Fourier transform infrared spectroscopy (FT-IR) and Raman spectroscopic (RS) studies. In dry air, the degradation of tebipenem was a first-order reaction depending on the substrate concentration while at an increased relative air humidity tebipenem was degraded according to the kinetic model of autocatalysis. The thermodynamic parameters: energy of activation (Ea), enthalpy (ΔH(≠a)) and entropy (ΔS(≠a)) of tebipenem degradation were calculated. Following a spectroscopic analysis of degraded samples of tebipenem, a cleavage of the β-lactam bond was proposed as the main degradation pathway, next confirmation using HPLC-Q-TOF-MS/MS method | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Kinetic and thermodynamic analysis | |
| 650 | 4 | |a solid-state stability | |
| 650 | 4 | |a tebipenem | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Carbapenems |2 NLM | |
| 650 | 7 | |a tebipenem |2 NLM | |
| 650 | 7 | |a Q2TWQ1I31U |2 NLM | |
| 700 | 1 | |a Lewandowska, Kornelia |e verfasserin |4 aut | |
| 700 | 1 | |a Garbacki, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Zalewski, Przemysław |e verfasserin |4 aut | |
| 700 | 1 | |a Skibiński, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Miklaszewski, Andrzej |e verfasserin |4 aut | |
| 700 | 1 | |a Mizera, Mikołaj |e verfasserin |4 aut | |
| 700 | 1 | |a Cielecka-Piontek, Judyta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug development and industrial pharmacy |d 1994 |g 42(2016), 2 vom: 22., Seite 238-44 |w (DE-627)NLM077783093 |x 1520-5762 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2016 |g number:2 |g day:22 |g pages:238-44 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3109/03639045.2015.1044902 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2016 |e 2 |b 22 |h 238-44 | ||